Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond
Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond
复制标题
DOI：
10.1016/s1470-2045(06)70693-3
复制
发表时间：
2006-05-01
期刊：
影响因子：
51.1
通讯作者：
Traynor, Anne M.
中科院分区：
文献类型：
--
作者：
Dubey, Sarita;Siegfried, Jill M.;Traynor, Anne M.
早期筛查，辅助和顺序的全身治疗以及荷尔蒙治疗在治疗乳腺癌方面有好处。非小细胞肺癌（NSCLC）的管理正在进行中，并有望跟随与乳腺癌相同的脚步。直到最近，临床试验才确立辅助治疗作为肺癌的护理标准。当在乳腺癌和NSCLC中用作顺序治疗时，越来越多的有效细胞毒性和靶向剂导致生存增加。肺部受体（ER）在肺部和表皮生长因子受体（EGFR）中的相互作用表明内分泌操纵在NSCLC治疗中的潜在作用。这种复杂的相互作用涉及几种类型的ER受体和不同的信号通路。烟草和雌激素之间的相互作用混淆了外源雌激素对肺癌风险的影响，但对乳腺癌的风险却不存在。荷尔蒙操纵以预防或治疗肺癌的最佳应用将取决于对肺特异性ER信号传导的更完整的理解。早期试验评估了ER和EGFR信号传导之间的相互作用。
Early screening, adjuvant and sequential systemic treatment, and hormonal therapy have benefits in treatment of breast cancer. Management of non-small-cell lung cancer (NSCLC) is progressing and will hopefully follow in the same footsteps as that of breast cancer. Only recently have clinical trials established adjuvant treatment as the standard of care in lung cancer. A growing number of effective cytotoxic and targeted agents have resulted in increased survival when used as sequential treatment in both breast cancer and NSCLC. The interaction between oestrogen receptors (ER) in the lung and epidermal growth factor receptor (EGFR) suggests a potential role for endocrine manipulation in the treatment of NSCLC. This complex interaction involves several types of ER receptors and different signalling pathways. Interactions between tobacco and oestrogen confound the effects of exogenous oestrogens on risk of lung cancer, but not on that of breast cancer. The optimum application of hormonal manipulation to prevent or treat lung cancer will depend on a more-complete understanding of lung-specific ER signalling. Early trials have assessed the interaction between the ER and EGFR signalling.